Therapeutic options in VEXAS syndrome: insights from a retrospective series
Estelle Bourbon(Université Claude Bernard Lyon 1), Pierre Sujobert(Université Claude Bernard Lyon 1), Thomas Barba(Lyon 1 Université), Mathieu Gerfaud Valentin(Hôpital de la Croix-Rousse), Fiorenza Barraco(Hôpital Lyon Sud), Cécile‐Audrey Durel(Lyon 1 Université), P. Sève(Hospices Civils de Lyon), Yvan Jamilloux(Hospices Civils de Lyon), Jean‐Christophe Lega(Lyon 1 Université), Maël Heiblig(Université Claude Bernard Lyon 1)
Cited by 283
Related Papers
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions
|Autoimmunity Reviews|2020|693
Sarcoidosis: A Clinical Overview from Symptoms to Diagnosis
|Cells|2021|458
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*
|British Journal of Dermatology|2021|414
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309